A Phase 2 interventional study of Metformin in Infertility Female, sponsored by The Baruch Padeh Medical Center, Poriya. Status unknown. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2016-07-29.
Sponsored by The Baruch Padeh Medical Center, Poriya · Phase 2, Interventional, and Treatment
The basis for obesity's impact on reproduction is not well characterised and there is a controversy whether the key organ influenced by it are the ovaries or the uterus.
Insulin sensitizers ameliorate insulin resistance in obese patients. This study seeks to determine if Metformin helps to increase fecundability by affecting the uterus in women undergoing ART. As a surrogate marker- flows in the uterus will be tested during the treatment.
Obesity has been long implicated in reduced reproductive potential and it has been shown to impair conception and implantation. However, the basis for this adverse effect is still obscure and there is a controversy whether the key organ influenced by it are the ovaries or the uterus.
It is well established that insulin resistance is one of the main mechanisms of obesity's negative influences on the reproductive organs in females. Insulin sensitizers ameliorate insulin resistance in obese patients.
This study seeks to determine if Metformin ,an oral antidiabetic and insulin sensitizer, helps to increase fecundability by affecting the uterus in women undergoing frozen-thawed embryo transfer compared to the control group. As a surrogate marker- flows in the uterus will be tested during the treatment.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's planned enrollment of 100 is below the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →The Baruch Padeh Medical Center, Poriya is the lead sponsor of 39 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
drug: metformin
Drug: Metformin
without metformin
Supplementation of the study group with Metformin till the day of pregnancy confirmation
Also known as: glucophage
pregnancy rate
Time frame: until the blood test for pregnancy, about 4-6 weeks
The changes in Doppler blood flow indices in both uterine arteries
Time frame: until the blood test for pregnancy, about 4-6 weeks
endometrial thickness change measured by millimeters
Time frame: until the blood test for pregnancy, about 4-6 weeks
Endometrial Doppler flows measured by power doppler - percentage of endometrium with flows
Time frame: until the blood test for pregnancy, about 4-6 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Baruch Padeh Medical Center, Poriya